BMEA 250117 22.50P (BMEA250117P22500) Stock Options, News & Quotes

18.28
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

我要向钱看

Jan 13 08:07

UPDATES

$Biomea Fusion (BMEA.US)$ Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
1.0% HbA1c reduction in patients on GLP-1-based therapies
100% response ...

Jaguar8

Jan 13 08:05

NEWS

$Biomea Fusion (BMEA.US)$
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Monday, 13th January at 9:00 am
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones
of the metabolic franchise
Biomea preparing icovamenib for late-stage clinical development
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company...

我要向钱看

Jan 10 07:13

🤔🤔🤔

$Biomea Fusion (BMEA.US)$ Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital

我要向钱看

Jan 7 08:21

NEW PRECLINICAL DATA

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...

我要向钱看

Jan 7 08:09

UPDATES

$Biomea Fusion (BMEA.US)$ REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Confer...